Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Lizinna 250 microgram /35 microgram Tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Ethinylestradiol, Norgestimate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Ethinylestradiol, Norgestimate
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Lizinna 250 microgram/35 microgram Tablets

Norgestimate/ethinylestradiol

Lizinna is a combined hormonal contraceptive pill ('the Pill'). You take it to stop getting pregnant. This contraceptive contains two types of female sex hormones, oestrogen and progestogen. These hormones prevent an egg being released from your ovaries so you cannot get pregnant. Also, Lizinna makes the fluid (mucus) in your cervix thicker which makes it more difficult for sperm to enter the womb. Lizinna is a 21-day Pill – you take one each day for 21 days, followed by 7 days when you take no pills. The benefits of taking the Pill include:

  • it is one of the most reliable reversible methods of contraception if used correctly
  • it doesn't interrupt sex
  • it usually makes your periods regular, lighter and less painful
  • it may help with pre-menstrual symptoms Lizinna will not protect you against sexually transmitted infections, such as Chlamydia or HIV. Only condoms can help to do this. Lizinna needs to be taken as directed to prevent pregnancy.

What you need to know before you take it

e Lizinna

928776

General notes Before you start using Lizinna you should read the information on blood clots in section 2.1. It is particularly important to read the symptoms of a blood clot – see Section 2.1 'The Pill and blood clots'. It is important that you understand the benefits and risks of taking Lizinna before you start taking it, or when deciding whether to carry on taking it. Although Lizinna is suitable for most healthy women it is not suitable for everyone. →Tell your doctor if you have any of the illnesses or risk factors mentioned in this leaflet. Before you start taking the Pill

  • Your doctor will ask about you and your family's medical problems and check your blood pressure. You may also need other checks, such as a breast examination but only if these are necessary for you or you have any special concerns. While you're on the Pill
  • You will need regular check-ups with your doctor or family planning nurse, usually when you need another prescription of Lizinna.
  • You should go for regular cervical smear tests.
  • Check your breasts and nipples every month for changes – tell your doctor if you can see or feel anything odd, such as lumps or dimpling of the skin.
  • If you need a blood test tell your doctor that you are taking Lizinna, because it can affect the results of some tests.
  • If you're going to have an operation, make sure your doctor knows about it. You may need to stop taking Lizinna about 4-6 weeks before the operation. This is to reduce the risk of a blood clot (see section 2.1). Your doctor will tell you when you can start taking Lizinna again. 2.1. The Pill and blood clots Using a Pill such as Lizinna increases your risk of developing a blood clot compared with not using one. In rare cases a blood clot can block blood vessels and cause serious problems. Blood clots can develop
  • in veins (referred to as ana 'venous thrombosis', 'venous thromboembolism' or VTE)
  • in the arteries (referred to as an 'arterial thrombosis', 'arterial thromboembolism' or ATE) Recovery from blood clots is not always complete. Rarely, there may be serious lasting effects or very rarely they may be fatal. It is important to remember that the overall risk of a harmful blood clot caused by Lizinna is small. How to recognise a blood clot Seek urgent medical attention if you notice any of the following signs or symptoms. Do you have any of these signs?
  • swelling of one leg or along a vein in the leg or foot especially with: o pain or tenderness in the leg which may be felt only when standing or walking o increased warmth in the affected leg o change in colour of the skin on the leg such as turning pale, red or blue.
  • sudden unexplained breathlessness or rapid breathing
  • sudden cough without an obvious cause, which may bring up blood
  • sharp chest pain which may increase with deep breathing
  • severe light headedness or dizziness
  • rapid or irregular heartbeat
  • severe pain in your stomach If you are unsure, talk to a doctor as some of these symptoms such as coughing or being short of breath may be mistaken for a milder condition such as a respiratory tract infection (like a common cold).

What could you be suffering from? Deep vein thrombosis (DVT) (blood clot in the large vein of the leg)

symptoms most commonly in one eye:

  • immediate loss of vision or
  • painless blurring of vision which can become a loss of vision.
  • chest pain or discomfort, pressure,
  • heaviness
  • sensation of squeezing or fullness in the chest, arm or below the breastbone
  • fullness, indigestion or choking feeling
  • upper body discomfort spreading out to the back, jaw, throat, arm and stomach
  • sweating, nausea, vomiting or dizziness
  • extreme weakness, anxiety, or shortness of breath
  • rapid or irregular heartbeats.

Retinal vein thrombosis (blood clot in the eye)

Pulmonary embolism (PE) (blood clot in the lungs)

Heart attack

  • sudden weakness or numbness of the face, arm or leg, especially on one side Stroke of the body (blood clot in the brain)
  • sudden confusion, trouble speaking or understanding
  • sudden trouble seeing in one or both eyes
  • sudden trouble walking, dizziness, loss of balance or coordination
  • sudden, severe or prolonged headache with no known cause
  • loss of consciousness or fainting with or without seizure. Sometimes the symptoms of a stroke can be brief with an almost immediate and full recovery, but you should still seek urgent medical attention as you may be at risk of another stroke.
  • swelling and slight blue discolouration of an extremity such as hands and feet Blood clots blocking other blood vessels
  • severe pain in your stomach (acute abdomen) Blood clots in a vein What can happen if a blood clot forms in a vein?
  • The use of combined hormonal contraceptives has been connected with an increase in the risk of blood clots in the vein (venous thrombosis). However, these side effects are rare. Most frequently, they occur in the first year of use of a combined hormonal contraceptive.
  • If a blood clot forms in a vein in the leg or foot it can cause a deep vein thrombosis (DVT)
  • If a blood clot travels from the leg and lodges in the lung it can cause a pulmonary embolism
  • Very rarely a clot may form in a vein in another organ such as the eye (retinal vein thrombosis). When is the risk of developing a blood clot in a vein highest? The risk of developing a blood clot in a vein is highest during the first year of taking the Pill for the first time. The risk may also be higher if you restart taking the Pill (the same product or a different product) after a break of 4 weeks or more. After the first year, the risk gets smaller but is always slightly higher than if you were not using the Pill. When you stop using Lizinna your risk of a blood clot returns to normal within a few weeks. What is the risk of developing a blood clot? The risk depends on your natural risk of VTE and the type of Pill you are taking. The overall risk of a blood clot in the leg or lung (DVT or PE) with Lizinna is small.
  • Out of 10,000 women who are not using any combined hormonal contraceptive and are not pregnant, about 2 will develop a blood clot in a year.
  • Out of 10,000 women taking a Pill containing levonorgestrel or norethisterone, or norgestimate such as Lizinna, about 5-7 will develop a blood clot in a year.
  • The risk of having a blood clot will vary according to your personal medical history (see "Factors that increase your risk of a blood clot" below). Risk of developing a blood clot in a year Women who are not using a combined hormonal Pill/patch/ring and are not About 2 out of 10,000 women pregnant Women using a Pill containing levonorgestrel, norethisterone or norgestimate About 5-7 out of 10,000 women Women using Lizinna

About 5-7 out of 10,000 women

Factors that increase your risk of a blood clot in a vein The risk of a blood clot with Lizinna is small but some conditions will increase the risk. Your risk is higher:

  • if you are very overweight (body mass index or BMI over 30 kg/m2)
  • if one of your immediate family has had a blood clot in the leg, lung or other organ at a young age (such as, below the age of about 50 years old). In this case you could have a hereditary blood clotting disorder
  • if you need to have an operation or if you are off your feet for a long time because of an injury or illness, or you have your leg in a cast. The use of Lizinna may need to be stopped for several weeks before surgery or while you are less mobile. If you need to stop Lizinna ask your doctor when you can start using it again
  • as you get older (particularly above about 35 years)
  • if you gave birth less than a few weeks ago. The risk of developing a blood clot increases the more conditions you have. Air travel (for longer than 4 hours) may temporarily increase your risk of a blood clot, particularly if you have some of the other risk factors listed. → It is important to tell your doctor if any of these risk factors apply to you, even if you are unsure. Your doctor may decide that Lizinna needs to be stopped. If any of the above conditions change while you are using Lizinna, for example a close family member has a thrombosis for no known reason or you gain a lot of weight, tell your doctor. Blood clots in an artery What can happen if a blood clot forms in an artery? Like a blood clot in a vein, a clot in an artery can cause serious problems. For example, it can cause a heart attack or a stroke. Factors that increase your risk of a blood clot in an artery It is important to note that the risk of a heart attack or stroke from using Lizinna is very small but can increase:
  • with increasing age (particularly above about 35 years old)
  • if you smoke. When using a Pill like Lizinna you are advised to stop smoking. If you are unable to stop smoking and are older than 35, your doctor may advise you to use a different type of contraceptive
  • if you are overweight
  • if you have high blood pressure
  • if a member of your immediate family has had a heart attack or stroke at a young age (less than about 50). In this case you could also have a higher risk of having a heart attack or stroke
  • if you or someone in your immediate family has a high level of fat in the blood (cholesterol or triglycerides)
  • if you get migraines, especially migraines with aura
  • if you have a problem with your heart (valve disorder, disturbance of the rhythm called atrial fibrillation)
  • if you have diabetes. If you have more than one of these conditions or if any of them are particularly severe the risk of developing a blood clot may be increased even more. →Tell your doctor if any of these risk factors applies to you. If any of the above conditions change while you are using Lizinna, for example you start smoking, a close family member has a thrombosis for no known reason, or you gain a lot of weight, tell your doctor. Taking the Pill may add to these risks so Lizinna may not be suitable for you. 2.2. The Pill and cancer The Pill reduces your risk of cancer of the ovary and womb if used for a long time. However, it also seems to slightly increase your risk of cancer of the cervix – although this may be due to having sex without a condom, rather than the Pill. All women should have regular smear tests. If you have breast cancer, or have had it in the past, you should not take the Pill. The Pill slightly increases your risk of breast cancer. This risk goes up the longer you're on the Pill, but returns to normal within about 10 years of stopping it. Because breast cancer is rare in women under the age of 40, the extra cases of breast cancer in current and recent Pill users are small. For example:
  • Of 10,000 women who have never taken the Pill, about 16 will have breast cancer by the time they are 35 years old.
  • Of 10,000 women who take the Pill for 5 years in their early twenties, about 17-18 will have breast cancer by the time they are 35 years old.
  • Of 10,000 women who have never taken the Pill, about 100 will have breast cancer by the time they are 45 years old.
  • Of 10,000 women who take the Pill for 5 years in their early thirties, about 111 will have breast cancer by the time they are 45 years old. Your risk of breast cancer is higher:
  • as you get older
  • if you have a close relative (mother, sister or grandmother) who has had breast cancer
  • if you are seriously overweight → See a doctor as soon as possible if you notice any changes in your breasts, such as dimpling of the skin, changes in the nipple or any lumps you can see or feel. Taking the Pill has also been linked to liver diseases, such as jaundice and non-cancer liver tumors, but this is rare. Very rarely, the Pill has also been linked with some forms of liver cancer in women who have taken it for a long time. → See a doctor as soon as possible if you get severe pain in your stomach, or yellow skin or eyes (jaundice). You may need to stop taking Lizinna.

2.3. Lizinna should not be taken by some women

2.6. Taking Lizinna with food and drink

You should not take Lizinna if you have any of the conditions listed below. If you do have any of the conditions listed below, you must tell your doctor. Your doctor will discuss with you what other form of birth control would be more appropriate. →Tell your doctor or family planning nurse if you have any medical problems or illnesses. Do not take Lizinna if any of the following applies to you:

  • If you have (or have ever had) a blood clot in a blood vessel of your legs (deep vein thrombosis, DVT), your lungs (pulmonary embolism, PE) or other organs
  • If you know you have a disorder affecting your blood clotting (for instance, protein C deficiency, protein S deficiency, antithrombin-III deficiency, Factor V Leiden or antiphospholipid antibodies)
  • If you need an operation or if you are off your feet for a long time (see Section 2.1 'The Pill and blood clots')
  • If you have ever had a heart attack or stroke
  • If you have (or have ever had) angina pectoris (a condition that causes severe chest pain which may be a first sign of a heart attack) or transient ischaemic attack (TIA – temporary stroke symptoms)
  • If you have any of the following diseases that may increase your risk of a clot in the arteries:
  • severe diabetes with blood vessel damage
  • very high blood pressure
  • very high level of fat in the blood (cholesterol or triglycerides)
  • a condition called hyperhomocysteinaemia
  • If you have (or have ever had) a type of migraine called 'migraine with aura'
  • If you have breast or liver cancer
  • If you have or have recently had a severe liver disease
  • if you have hepatitis C and are taking the medicinal products containing ombitasvir/ paritaprevir/ritonavir, dasabuvir, glecaprevir/ pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see also section 2.5 'Other medicines and Lizinna Tablets')
  • If you are allergic to any of the ingredients in Lizinna. →If you suffer from any of these, or get them for the first time while taking Lizinna, contact your doctor as soon as possible. Do not take Lizinna as it may put your health at risk.

There are no special instructions about food and drink while on Lizinna.

2.4. Warnings and precautions When should you contact your doctor? Seek urgent medical attention

  • if you notice possible signs of a blood clot that may mean you are suffering from a blood clot in the leg (deep vein thrombosis), a blood clot in the lung (pulmonary embolism), a heart attack or a stroke (see Section 2.1 'The Pill and blood clots' above). For a description of the symptoms of these serious side effects please go to "How to recognise a blood clot". Tell your doctor if any of the following conditions applies to you If the condition develops, or gets worse while you are using Lizinna, you must also tell your doctor. You may still be able to take Lizinna but you need to take special care and have check-ups more often:
  • If you experience symptoms of angioedema such as swollen face, tongue and/or throat and/or difficulty swallowing or hives potentially with difficulty breathing contact a doctor immediately. Products containing estrogens may cause or worsen the symptoms of hereditary and acquired angioedema.
  • If you have problems with your heart, circulation or blood clotting, such as high blood pressure
  • If you have diabetes without secondary problems
  • If you have liver problems or gall bladder disease
  • If you have Crohn's disease or ulcerative colitis (chronic inflammatory bowel disease)
  • If you have systemic lupus erythematosus (SLE; a disease affecting your natural defence system)
  • If you have porphyria
  • If you have a history of migraines
  • If you have elevated levels of fat in the blood (hypertriglyceridaemia) or a positive family history for this condition. Hypertriglyceridaemia has been associated with an increased risk of developing pancreatitis (inflammation of the pancreas)
  • If you need an operation, or you are off your feet for a long time (see Section 2.1 'The Pill and blood clots')
  • If you have had any of the following problems while pregnant or during previous Pill use, such as itchy skin or blister-like rash, yellowing of skin or eyes, hearing problem, systemic lupus erythematosus (SLE), severe headaches, uncontrollable jerky movements
  • If you have just given birth you are at an increased risk of blood clots. You should ask your doctor how soon after delivery you can start taking Lizinna
  • If you have haemolytic uraemic syndrome (HUS, a disorder of blood clotting causing failure of the kidneys)
  • If you have sickle cell anaemia (an inherited disease of the red blood cells)
  • If you have varicose veins
  • If you have inflammation in the veins under the skin (superficial thrombophlebitis). →Tell your doctor or family planning nurse if any of these applies to you. Also tell them if you get any of these for the first time while taking the Pill, or if any get worse or come back, because you may need to stop taking Lizinna and use another method of contraception, such as condoms. Psychiatric disorders: Some women using hormonal contraceptives including Lizinna have reported depression or depressed mood. Depression can be serious and may sometimes lead to suicidal thoughts. If you experience mood changes and depressive symptoms contact your doctor for further medical advice as soon as possible. Other conditions •C  hloasma (yellow-brownish patches on your skin, pigment spots during pregnancy, especially on your face) occasionally occur, especially if you have had a history of it. You may need to keep out of the sun or away from sunbeds (these patches may not completely disappear again).

2.7. Pregnancy and breast-feeding Do not start to use Lizinna if you are pregnant. If you think you might be pregnant while taking Lizinna, do a pregnancy test to confirm that you are before you stop taking it. If you are breast-feeding, your doctor or family planning nurse may advise you not to take Lizinna. Talk to them about alternative contraception. Breast-feeding may not stop you getting pregnant. 2.8. Driving and using machines Lizinna has no known effect on the ability to drive or use machines. 2.9. Lizinna contains lactose and sodium If you have been told by your doctor that you have intolerance to some sugars contact your doctor before using Lizinna. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

How to take it

Lizinna 3.1. How to take it To prevent pregnancy, always take Lizinna as described below. Check with your doctor or family planning nurse if you are not sure. Take Lizinna every day for 21 days Lizinna comes in a strip of 21 pills, each marked with a day of the week.

  • Take your pill at the same time every day.
  • Start by taking a pill marked with the correct day of the week.
  • Follow the direction of the arrows on the strip. Take one pill each day.
  • Swallow each pill whole, with water if necessary. Do not chew the pill. Then have seven pill-free days After you have taken all 21 pills in the strip, you have seven days when you take no pills. So, if you take the last pill of one pack on a Friday, you will take the first pill of your next pack on the Saturday of the following week. Within a few days of taking the last pill from the strip, you should have a withdrawal bleed like a period. This bleed may not have finished when it is time to start your next strip of pills. You don't need to use extra contraception during these seven pill-free days – as long as you have taken your pills correctly and start the next strip of pills on time. Then start your next strip Start taking your next strip of Lizinna after the seven pill-free days – even if you are still bleeding. Always start the new strip on time. As long as you take Lizinna correctly, you will always start each new strip on the same day of the week. 3.2. Starting Lizinna As a new user or starting the Pill again after a break Either take your first Lizinna pill up to and including day 5 of your next period (counting the first day of your period as day 1). This way, you will have contraceptive protection with your first pill. Or start taking Lizinna at any time, if you are sure you are not already pregnant. But then you must use extra contraception, such as condoms, until you have taken the first 7 pills correctly. Changing to Lizinna from another contraceptive If you are currently taking another Pill and you are taking it correctly, you can start Lizinna at any time, if you are sure you are not already pregnant. There is no need to wait for your next period to start and you don't need extra contraception. If you are currently using a non-hormonal method and your period started more than 5 days ago, you must use extra contraception, such as condoms, until you have taken the first 7 pills correctly. Starting Lizinna after a miscarriage or abortion If you have had a miscarriage or an abortion, your doctor may tell you to start taking Lizinna straight away. This means that you will have contraceptive protection with your first pill. Contraception after having a baby If you have just had a baby, you are more at risk of blood clots (see Section 2.1, 'The Pill and blood clots'). Ask your doctor when you can start taking Lizinna again. If it is 21 days after the birth, you will have contraceptive protection with your first pill. If you start Lizinna after this, you must use extra contraception, such as condoms, until you have taken the first 7 pills correctly. 3.3. A missed pill Missing pills or starting a strip late may make your pill less effective. The chance of pregnancy after missing pills depends on when pills are missed and how many pills are missed. Missing one pill anywhere in your strip or starting a new strip one day late is not a problem. Missing more than one or starting a strip more than one day late may affect your contraceptive cover. It is more risky to start a strip late and miss more than one pill. How many pills have you missed?

2.5. Other medicines and Lizinna If you ever need to take another medicine at the same time as being on the Pill, always tell your doctor, pharmacist or dentist that you're taking Lizinna. Also check the leaflets that come with all your medicines to see if they can be taken with hormonal contraceptives. Some medicines can stop Lizinna from working properly – for example:

  • some medicines used to treat epilepsy (such as topiramate, carbamazepine, phenytoin, fosphenytoin, oxcarbazepine, felbamate, primidone, eslicarbazepine acetate, rufinamide)
  • bosentan (for high blood pressure in the blood vessels of the lungs)
  • certain medicines for tuberculosis such as rifampicin and rifabutin
  • anti-HIV medicines
  • boceprevir and telaprevir (for treatment of Hepatitis C infections)
  • aprepitant and fosaprepitant (for prevention of nausea and vomiting caused by certain cancer drug treatment)
  • griseofulvin (for fungal infections)
  • modafinil (for excessive daytime sleepiness)
  • certain sedatives (called 'barbiturates')
  • St. John's Wort (a herbal remedy)
  • metoclopramide (to increase movement through the gut)
  • charcoal
  • colesevelam (to treat high cholesterol levels)
  • etoricoxib (to help with pain and inflammation of arthritis) If you do need to take one of these medicines, Lizinna may not be suitable for you or you may need to use extra contraception for a while. Your doctor, pharmacist or dentist can tell you if this is necessary and for how long. Lizinna can also affect other medicines- for example:
  • ciclosporin (to prevent transplant rejection and for rheumatoid arthritis or some skin problems)
  • lamotrigine (for epilepsy)
  • prednisolone (a steroid to reduce inflammation)
  • selegiline (for Parkinson's disease)
  • theophylline (for asthma, bronchitis and emphysema)
  • tizanidine (used to relax muscles) Talk to your doctor before having Lizinna if you are taking any of these medicines. They may have to change how much of these medicines you are taking. Do not use Lizzina Tablets if you have hepatitis C and are taking the medicinal products containing ombitasvir/paritaprevir/ritonavir, dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, as these products may cause increases in liver function blood test results (increase in ALT liver enzyme). Your doctor will prescribe another type of contraceptive prior to start of the treatment with these medicinal products. Lizzina Tablets can be restarted approximately 2 weeks after completion of this treatment. See section 2.3 'Do not take Lizzina if any of the following applies to you:'

Two or more pills

One pill

  • Take the missed pill straight

away, and further pills as usual. This may mean taking two pills in one day.

  • Continue taking the rest of the strip as usual.
  • Don't worry – your contraceptive protection should not be reduced.
  • Take the most recently missed pill straight away
  • Leave any earlier missed pills in the strip
  • Take your next pill at the usual time. This may mean taking two pills in one day.
  • Continue taking the rest of the strip as usual.
  • Use extra precautions (condoms, for instance) for the next 7 days.
  • Check how many pills are left in the strip after the most recently missed pill 7 or more pills left in the pack
  • Use extra precautions for the next 7 days
  • When you have finished the strip, leave the

usual 7-day break before starting the next strip.

  • If you have missed any pills from the first week of your strip and you had sex in that week, you could become pregnant. Contact your doctor, family planning nurse or pharmacist for advice as soon as possible. They may recommend you use emergency contraception.

Fewer than 7 pills left in the pack

  • Use extra precautions for the next 7 days
  • When you finish the strip, start the next strip the next day without a break.
  • If you do not have a withdrawal bleed after you have finished the second strip, do a pregnancy test

If you have missed any of the pills in a strip, and you do not bleed in the first pill-free break, you may be pregnant. Contact your doctor or family planning clinic, or do a pregnancy test yourself.

If you start a new strip of pills late, or make your 'week off' longer than eight days, you may not be protected from pregnancy. If you had sex in the last seven days, ask your doctor, family planning nurse or pharmacist for advice. You may need to consider emergency contraception. You should also use extra contraception, such as a condom, for seven days. 3.4. A lost pill If you lose a pill, just take a pill from a spare strip. Then take all the other pills from your current strip as usual. You can then keep the opened spare strip in case you lose any more pills. 3.5. If you are sick or have diarrhoea If you are sick or have very bad diarrhoea, your body may not get its usual dose of hormones from that pill. If you have been sick within 2 hours of taking Lizinna, just take a pill from a spare strip. Carry on taking your pills as normal if you can. You won't need to use extra contraception. If you are still sick or have diarrhoea for more than 1 day, follow the instructions for a missed pill – see section 3.3, A missed pill. →Talk to your doctor if your stomach upset carries on or gets worse. He or she may recommend another form of contraception. 3.6. Missed a period – could you be pregnant? Occasionally, you may miss a withdrawal bleed. This could mean that you are pregnant, but that is very unlikely if you have taken your pills correctly. Start your next strip at the normal time. If you think that you might have put yourself at risk of pregnancy (for example, by missing pills or taking other medicines), or if you miss a second bleed, you should do a pregnancy test. You can buy these from the chemist or get a free test at your family planning clinic or doctor's surgery. If you are pregnant, stop taking Lizinna and see your doctor. 3.7. Taking more than one pill should not cause harm It is unlikely that taking more than one pill will do you any harm, but you may feel sick, vomit or have some vaginal bleeding. Talk to your doctor if you have any of these symptoms. 3.8. You can delay a period If you want to delay having a period, finish the strip of pills you are taking. Start the next strip the next day without a break. Pill taking should then continue as usual. When you use the second strip, you may have some unexpected bleeding or spotting on the days that you take the pill, but don't worry. Take the next strip after the usual 7 day break even if you are still bleeding or spotting. 3.9. When you want to get pregnant If you are planning a baby, it is best to use another method of contraception after stopping Lizinna until you have had a proper period. Your doctor or midwife relies on the date of your last natural period to tell you when your baby is due. The Pill may reduce the levels of folic acid in the blood. Talk to your doctor, nurse or pharmacist as this could be important if you get pregnant straight after stopping the Pill.

  • Hot flushes
  • Muscle pain
  • Vaginal dryness
  • Ovarian cysts (may cause pain and swelling of the abdomen, changes in periods) Rare side effects (affects fewer than 1 in 1000 patients)
  • Lumpy breasts
  • Loss of sex drive
  • Feeling giddy
  • Faster heart beat
  • Pancreatitis (inflammation of the pancreas, which causes severe pain in the abdomen and back)
  • Increased sweating
  • Sensitivity to light Frequency not known
  • Reduced amount of breast milk (if breast feeding)
  • Contact lenses may feel uncomfortable
  • Red painful lumpy swellings on the legs
  • Changes in fat levels in the blood (seen by blood tests)
  • Night sweats.
  • liver enzymes increased (transaminase elevation). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. Also tell your doctor, pharmacist or nurse if any existing conditions get worse while you are taking Lizinna. 4.3. Bleeding between periods should not last long Usually you should only have a withdrawal bleed like a period during the seven pill-free days. However, a few women have a little unexpected bleeding or spotting while they are taking Lizinna, especially during the first few months. Normally, this bleeding is nothing to worry about and will stop after a day or two. Keep taking Lizinna as usual. The problem should disappear after the first few strips. You may also have unexpected bleeding if you are not taking your pills regularly, so try to take your pill at the same time every day. Also, unexpected bleeding can sometimes be caused by other medicines. → Make an appointment to see your doctor if you get breakthrough bleeding or spotting that:
  • carries on for more than the first few months
  • starts after you've been taking Lizinna for a while
  • carries on even after you've stopped taking Lizinna.

Possible side effects

4.2. Other possible side effects – tell your doctor Very common side effects (affects more than 1 in 10 patients)

  • Headache (but if severe, unusual or long lasting, see a doctor as soon as possible)
  • Stomach problems such as nausea, vomiting and diarrhoea
  • Bleeding and spotting between your periods for the first few months (though this usually stops when your body adjusts to Lizinna) – see section 4.3, Bleeding between periods should not last long
  • Painful or unusual periods Common side effects (affects more than 1 in 100 patients)
  • Migraine (see a doctor as soon as possible if this is your first migraine or it's worse than usual)
  • Swollen hands, ankles or feet
  • Depression; mood changes; feeling nervous or dizzy
  • Difficulty sleeping (insomnia)
  • Stomach ache and bloating; constipation; wind
  • Acne; rash
  • Muscle spasms; pain in the legs, arms and back
  • Painful breasts
  • Urinary tract infections (pain on passing urine)
  • Vaginal infections such as thrush
  • Vaginal discharge
  • No menstrual periods
  • Feeling weak
  • Weight gain. Uncommon side effects (affects fewer than 1 in 100 patients)
  • Breast problems, such as fuller breasts; producing fluid from the nipples
  • Abnormal cells in the cervix (identified by a smear test)
  • Feeling anxious or faint; tingling sensation or numbness
  • Changes in skin colour
  • Skin problems such as redness and itchiness
  • Hair thinning (alopecia), excessive hair growth
  • Changes in appetite
  • Weight may vary
  • Change in sex drive
  • Dry eyes
  • Changes in vision
  • Palpitations (feeling your heart beat)

This leaflet was last revised in April 2025

928776-01

MPL13958 – P1.1

Artwork for: Morningside Pharmaceuticals Ltd Product name: Lizinna 250mcg/ 35mcg tablets Size: 21 tablets PL/PA no: PL 20117/0220 Type: Leaflet Artwork dimensions: 860mm x 430mm Reason for request: Type IAin bulk submission (comma, alpha) Version no: 1.1 Date of revision: 11.5.26 Colours: As swatches Font(s): Nimbus Sans A/W software: Indesign CC

Black

How to store it

Lizinna

Like all medicines, this medicine can cause side effects, although not everybody gets them. →Tell your doctor, pharmacist or family planning nurse if you get any side effect particularly if they are severe and persistent, or you have any change in your health which you think may be due to Lizinna.

Keep this medicines out of the sight and reach of children. Do not use Lizinna after the expiry date shown on the strip. The expiry date refers to the last day of that month. Store in the original package to protect from light. Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

4.1. Serious side effects – see a doctor straight away

Contents of the pack and other information

Contact a doctor immediately if you experience any of the following symptoms of angioedema: swollen face, tongue and/or throat and/or difficulty swallowing or hives potentially with difficulty breathing (see also section "Warnings and precautions"). Harmful blood clots in a vein or artery (frequency not known) for example:

  • in a leg or foot (DVT)
  • in a lung (PE)
  • heart attack
  • stroke
  • mini-stroke or temporary stroke-like symptoms, known as a transient ischaemic attack (TIA)
  • blood clots in the liver, stomach/intestines, kidneys or eye. An increased risk of blood clots in your veins (venous thromboembolism, VTE) or arteries (arterial thromboembolism, ATE) is present for all women taking the Pill. For more detailed information on the different risks from taking the Pill, please see Section 2 'Make sure Lizinna is OK for you'. The chance of having a blood clot may be higher if you have any other conditions that increase this risk (see Section 2.1 'The Pill and blood clots' for more information on the conditions that increase risk for blood clots and the symptoms of a blood clot). Breast cancer (frequency not known) Signs include:
  • dimpling of the skin
  • changes in the nipple
  • any lumps you can see or feel. Severe liver problems (rare – affects fewer than 1 in 1000 patients) Signs include:
  • severe pain in your upper abdomen
  • yellow skin or eyes (jaundice). Other serious side effects include:
  • increased blood pressure (uncommon – affects fewer than 1 in 100 patients)
  • fits (convulsions) (frequency not known)
  • hives (urticaria) (uncommon – affects fewer than 1 in 100 patients), swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing. These may be signs of allergy. →If you think you may have any of these, see a doctor straight away. You may need to stop taking Lizinna.

What Lizinna contains

  • Each pill contains 250 micrograms norgestimate and 35 micrograms ethinylestradiol.
  • The other ingredients are Lactose Anhydrous, Lactose Monohydrate, Povidone K-25, dl-α-tocopherol, Microcrystalline cellulose, Croscarmellose sodium, Starch Pregelatinised (starch 1500), Magnesium Stearate, Indigo carmine aluminium lake (E 132). What Lizinna looks like and contents of the pack Lizinna tablets are round, blue, uncoated flat beveled edge tablets with '146' debossed on one side and plain on the other side, with a diameter of 6.4mm. They are supplied in packs containing: 21, 63, 126 tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder Morningside Healthcare Limited Unit C, Harcourt Way Leicester, LE19 1WP, UK Manufacturer Morningside Pharmaceuticals Ltd 5 Pavilion Way, Castle Business Park Loughborough, Leicestershire LE11 5GW, UK Morningside Pharmaceuticals Ltd. & Aspire Pharma Ltd. Second Floor, Boss Court 7 Barton Close, Grove Park Leicester, LE19 1SJ, UK Aspire Pharma Ltd. Unit 4, Rotherbrook Court Bedford Road, Petersfield Hampshire, GU32 3QG, UK

Frequently asked questions about Lizinna 250 microgram /35 microgram Tablets

How do I take Lizinna 250 microgram /35 microgram Tablets?

Lizinna 250 microgram /35 microgram Tablets comes as tablet containing 250mcg / 35mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Lizinna 250 microgram /35 microgram Tablets?

The active substance in Lizinna 250 microgram /35 microgram Tablets is ethinylestradiol, norgestimate.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Lizinna 250 microgram /35 microgram Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Lizinna 250 microgram /35 microgram Tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Ethinylestradiol, norgestimate (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Contraception and the recognised indications for such oestrogen/progestogen combinations.

The decision to prescribe Lizinna should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lizinna compares with other Combined Hormonal Contraceptives (CHCs) (see sections 4.3 and 4.4).

4.2. Posology and method of administration

For oral administration.

Adults

How to take Lizinna

One tablet is taken daily at the same time (preferably in the evening) without interruption for 21 days, followed by a break of 7 tablet-free days. Each subsequent pack is started after the 7 tablet-free days have elapsed. Additional contraceptive precautions are not then required. During the tablet-free period, bleeding can be expected, usually beginning 2 to 4 days after the last tablet.

Starting treatment

It is preferable that tablet intake from the first pack is started up to and including day 5 of menstruation in which case no extra contraceptive precautions are necessary.

Lizinna can be started at any other time, if pregnancy can reasonably be excluded. In this case additional contraceptive precautions must be taken for the first 7 days of tablet taking

Switching from another contraceptive

Hormonal methods: Lizinna can be started immediately if the patient has been using the current hormonal method consistently and correctly, or if pregnancy can reasonably be excluded. There is no need to wait for the next menstruation. Additional contraceptive precautions are not required.

Non-hormonal methods: If Lizinna is started after the first 5 days of menstruation, additional contraceptive precautions are required for the next 7 days.

Post-partum administration

Following a vaginal delivery, oral contraceptive administration to non-breast-feeding mothers can be started 21 days post-partum provided the patient is fully ambulant and there are no puerperal complications. No additional contraceptive precautions are required. If post-partum administration begins more than 21 days after delivery, additional contraceptive precautions are required for the first 7 days of pill-taking.

If intercourse has taken place post-partum, oral contraceptive use should be delayed until the first day of the first menstrual period.

For information on breast-feeding mothers, see section 4.6.

Use after Abortion or Miscarriage

After an abortion or miscarriage that occurs prior to 24 weeks gestation, oral contraceptives can be started immediately. An additional method of contraception is not needed.

After an induced or spontaneous abortion that occurs at or after 24 weeks gestation, hormonal contraceptives may be started either on Day 21 post-abortion or on the first day of the first spontaneous menstruation, whichever comes first. No additional contraceptive precautions are required.

To skip a period

To skip a period, a new pack of Lizinna should be started on the day after finishing the current pack (the patient skips the tablet-free days). Tablet-taking should be continued in the usual way.

During the use of the second pack she may experience slight spotting or break-through bleeding but contraceptive protection will not be diminished provided there are no tablet omissions.

The next pack of Lizinna is started after the usual 7 tablet-free days, regardless of whether the period has completely finished or not.

Reduced reliability

When Lizinna is taken according to the directions for use, the occurrence of pregnancy is highly unlikely. However, the reliability of oral contraceptives may be reduced under the following circumstances:

(i) Missed tablets

If the patient forgets to take one tablet or if a new strip is started one day late, she should take it as soon as she remembers and take the next one at the normal time. This may mean that two tablets are taken in one day. No additional contraceptive precautions are required. If more than one tablet is missed or if a new strip is started more than one day late, she should take the last missed tablet as soon as she remembers but leave the other missed tablets in the strip. She should continue to take the rest of the strip as usual but must use extra precautions (e.g. condom, diaphragm, plus spermicide) for the next 7 days.

If the tablets are missed:

• In week 1

If unprotected sex has taken place, the use of emergency contraception should be considered. The usual 7-day break can be left before starting the next strip.

• In week 2

The usual 7-day break can be left before starting the next strip.

• In week 3

When the strip is finished the next strip should be started the next day without a break. If withdrawal bleeding does not occur at the end of the second strip, a pregnancy test should be performed.

(ii) Vomiting or diarrhoea

If a patient vomits within two hours of taking a tablet she should take another tablet from a spare strip.

If severe vomiting or diarrhoea continues for more than one day, she should follow the procedure for missed tablets (and continue taking the tablets if she can).

Elderly:

Use of this product is not indicated in post-menopausal women.

Children:

Use of this product before menarche is not indicated.

4.3. Contraindications

• Presence or risk of venous thromboembolism (VTE)

o Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE])

o Known hereditary or acquired predisposition for venous thromboembolism, such as APC-resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency (see section 4.4)

o Major surgery with prolonged immobilisation (see section 4.4)

o A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4)

• Presence or risk of arterial thromboembolism (ATE)

o Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris)

o Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA)

o Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant)

o History of migraine with focal neurological symptoms

o A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:

- diabetes mellitus with vascular symptoms

- severe hypertension

- severe dyslipoproteinaemia

• Acute or chronic liver disease, including hepatitis (viral or non-viral) or severe cirrhosis, or a history of these conditions until at least 3 months after abnormal liver function tests have returned to normal; hepatic adenomas or carcinomas.

• Known or suspected carcinoma of the breast.

• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Should any of these conditions occur for the first time during use of Lizinna, the tablets should be discontinued immediately.

Lizinna is contraindicated for concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, medicinal products containing glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).

4.4. Special warnings and precautions for use

Warnings

If any of the conditions/risk factors mentioned below is present, the suitability of Lizinna should be discussed with the woman.

In the event of aggravation, or first appearance of any of these conditions or risk factors, the woman should be advised to contact her doctor to determine whether the use of Lizinna should be discontinued.

Exclude likelihood of pregnancy before starting treatment.

Undiagnosed vaginal bleeding should be investigated further.

Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives.

Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.

Medical examination/consultation

Prior to the initiation or reinstitution of Lizinna a complete medical history (including family history) should be taken and pregnancy must be ruled out. Blood pressure should be measured and a physical examination should be performed, guided by the contraindications (see section 4.3) and warnings (see section 4.4).

It is important to draw a woman's attention to the information on venous and arterial thrombosis, including the risk of Lizinna compared with other CHCs, the symptoms of VTE and ATE, the known risk factors and what to do in the event of a suspected thrombosis.

The woman should also be instructed to carefully read the user leaflet and to adhere to the advice given.

The frequency and nature of examinations should be based upon established practice guidelines and should be adapted to the individual woman.

Women should be advised that oral contraceptives DO NOT protect against HIV infections (AIDS) or any other sexually transmitted disease.

Conditions requiring supervision

- The theoretical or proven risks usually outweigh the advantages of using Combined Oral Contraceptives (COCs) in the conditions listed below. Consequently the decision to prescribe the COC must be made with specialist clinical judgement.

- Breast feeding (see section 4.6)

- Increased risk of venous thromboembolic disorders (See section 4.3 and “Circulatory disorders” below)

- Adequately controlled hypertension (persistently elevated baseline systolic values 140-159 mmHg or diastolic values 90-94 mmHg)

- Obesity (BMI ≥ 35kg/m2)

- History of cholestasis (related to COCs), current or medically treated gall bladder disease, porphyria

- History of breast cancer, 5 years disease-free.

Circulatory disorders

Risk of Venous Thromboembolism (VTE)

The use of any CHCs increases the risk of venous thromboembolism (VTE) compared with no use. Products that contain levonorgestrel, norgestimate (including Lizinna) or norethisterone are associated with the lowest risk of VTE. The decision to use Lizinna should be taken after a discussion with the woman to ensure she understands the risk of VTE with Lizinna, how her current risk factors influence this risk, and that her VTE risk is highest in the first ever year of use. There is also some evidence that the risk is increased when a CHC is re-started after a break in use of 4 weeks or more.

In women who do not use a CHC and are not pregnant, about 2 out of 10,000 will develop a VTE over the period of one year. However, in any individual woman the risk may be far higher, depending on her underlying risk factors (see below).

It is estimated that out of 10,000 women who use a CHC that contains levonorgestrel, about 6 will develop a VTE in a year.

Current evidence suggests that the risk of VTE with use of norgestimate-containing CHCs is similar to the risk with levonorgestrel-containing CHCs.

This number of VTEs per year is fewer than the number expected in women during pregnancy or in the postpartum period.

VTE may be fatal in 1-2% of cases.

Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels, e.g. hepatic, mesenteric, renal or retinal veins and arteries.

Risk factors for VTE

The risk for venous thromboembolic complications in CHC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors (see table).

Lizinna is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors – in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).

Table: Risk factors for VTE

Risk factor

Comment

Obesity (body mass index over 30kg/m2)

Risk increases substantially as BMI rises.

Particularly important to consider if other risk factors also present.

Prolonged immobilisation, major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma

Note: temporary immobilisation including air travel >4 hours can also be a risk factor for VTE, particularly in women with other risk factors

In these situations it is advisable to discontinue use of the Pill (in the case of elective surgery at least four weeks in advance) and not resume until two weeks after complete remobilisation. Another method of contraception should be used to avoid unintentional pregnancy.

Antithrombotic treatment should be considered if Lizinna has not been discontinued in advance.

Positive family history (venous thromboembolism ever in a sibling or parent especially at a relatively early age e.g. before 50)

If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.

Other medical conditions associated with VTE

Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease.

Increasing age

Particularly above 35 years old.

There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in the onset or progression of venous thrombosis.

The increased risk of thromboembolism in pregnancy, and particularly the 6 week period of the puerperium, must be considered (for information on “Pregnancy and lactation” see section 4.6).

Symptoms of VTE (deep vein thrombosis and pulmonary embolism)

In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.

• Symptoms of deep vein thrombosis (DVT) can include:

o unilateral swelling of the leg and/or foot or along a vein in the leg

o pain or tenderness in the leg which may be felt only when standing or walking

o increased warmth in the affected leg; red or discoloured skin on the leg.

• Symptoms of pulmonary embolism (PE) can include:

o sudden onset of unexplained shortness of breath or rapid breathing

o sudden coughing which may be associated with haemoptysis

o sharp chest pain

o severe light headedness or dizziness

o rapid or irregular heartbeat.

Some of these symptoms (e.g. shortness of breath, coughing) are non-specific and might be misinterpreted as more common or less severe events (e.g. respiratory tract infections).

Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discolouration of an extremity.

If the occlusion occurs in the eye symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately.

Risk of arterial thromboembolism (ATE)

Epidemiological studies have associated the use of CHCs with an increased risk for arterial thromboembolism (e.g. myocardial infarction) or for cerebrovascular accident (e.g. transient ischaemic attack, stroke). Arterial thromboembolic events may be fatal.

Risk factors for ATE

The risk of arterial thromboembolic complications or of a cerebrovascular accident in CHC users increases in women with risk factors (see table). Lizinna is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors - in this case her total risk should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).

Table: Risk factors for ATE

Risk factor

Comment

Increasing age

Particularly above 35 years old.

Smoking

Women should be advised not to smoke if they wish to use a CHC. Women over 35 years old who continue to smoke should be strongly advised to use a different method of contraception.

Hypertension

Obesity (body mass index over 30kg/m2)

Risk increases substantially as BMI increases.

Particularly important in women with additional risk factors.

Positive family history (arterial thromboembolism ever in a sibling or parent especially at a relatively early age e.g. below 50 years old).

If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use.

Migraine

An increase in frequency or severity of migraine during CHC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation.

Other medical conditions associated with adverse vascular events

Diabetes mellitus, hyperhomocysteinaemia, valvular heart disease and atrial fibrillation, dyslipoproteinaemia and systemic lupus erythematosus.

Symptoms of ATE

In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.

• Symptoms of a cerebrovascular accident can include:

o sudden numbness or weakness of the face, arm or leg, especially on one side of the body

o sudden trouble walking, dizziness, loss of balance or coordination

o sudden confusion, trouble speaking or understanding

o sudden trouble seeing in one or both eyes

o sudden, severe or prolonged headache with no known cause

o loss of consciousness or fainting with or without seizure.

Temporary symptoms suggest the event is a transient ischaemic attack (TIA).

• Symptoms of myocardial infarction (MI) can include:

o pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone

o discomfort radiating to the back, jaw, throat, arm, stomach

o feeling of being full, having indigestion or choking

o sweating, nausea, vomiting or dizziness

o extreme weakness, anxiety, or shortness of breath

o rapid or irregular heartbeats.

Hepatic adenomas

Malignant hepatic tumours have been reported on rare occasions in long-term users of oral contraceptives. Benign hepatic tumours have also been associated with oral contraceptive usage. A hepatic tumour should be considered in the differential diagnosis when upper abdominal pain, enlarged liver or signs of intra-abdominal haemorrhage occur. In isolated cases, life-threatening intra-abdominal haemorrhage may occur.

Breast cancer

A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using COCs. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The additional breast cancers diagnosed in current users of COCs or in women who have used COCs in the last 10 years are more likely to be localised to the breast than those in women who never used COCs.

Breast cancer is rare among women under 40 years of age whether or not they take COCs. Whilst this background risk increases with age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer (see bar chart).

The most important risk factor for breast cancer in COC users is the age women discontinue the COC; the older the age at stopping, the more breast cancers are diagnosed. Duration of use is less important and the excess risk gradually disappears during the course of the 10 years after stopping COC use such that by 10 years there appears to be no excess.

The possible increase in risk of breast cancer should be discussed with the user and weighed against the benefits of COCs taking into account the evidence that they offer substantial protection against the risk of developing certain other cancers (e.g. ovarian and endometrial cancer).

Cervical cancer

The most important risk factor for cervical cancer is persistent Human Papilloma Virus (HPV) infection. Some epidemiological studies have indicated that long-term use of COCs may further contribute to this increased risk but there continues to be controversy about the extent to which this finding is attributable to confounding effects, e.g. cervical screening and sexual behaviour including use of barrier contraceptives.

There is some theoretical concern that COCs enhance progression of Cervical Intraepithelial Neoplasia (CIN) to invasive disease. For women with diagnosed cervical cancer, COCs may be used whilst awaiting treatment.

Other tumours

Numerous epidemiological studies have been reported on the risk of ovarian and endometrial cancer in women using COCs. The evidence is clear that COCs offer substantial protection against both ovarian and endometrial cancer.

Bleeding irregularities

Breakthrough bleeding, spotting and/or absence of withdrawal flow may be encountered in patients on oral contraceptives, especially during the first three months of use.

If bleeding irregularities persist beyond three cycles or occur after previously regular cycles, non-hormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy.

Some woman may experience post-Pill amenorrhoea or oligomenorrhoea, especially when such a condition was pre-existing.

Laboratory tests

In the literature, at least a hundred different laboratory test parameters have been reported to be possibly influenced by oral contraceptive use, predominantly by the oestrogenic component. Among these are: biochemical parameters of the liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins and lipid/lipoprotein fractions and parameters of coagulation and fibrinolysis.

Other conditions

In the following conditions the benefit of oral contraception generally outweighs the theoretical or known risk. However, they may need to be considered before prescribing to individual patients:

• Known hyperlipidaemias. A small proportion of women will have persistent hypertriglyceridemia while on the Pill. Changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. However, routine screening of women with hypertriglyceridaemia is not considered appropriate. Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.

• Diabetes without vascular involvement (although all patients with diabetes are at increased risk of arterial disease).

• Decreased glucose tolerance. The oestrogen component of Lizinna may cause a decrease in glucose tolerance, while the progestogens may increase insulin secretion and create insulin resistance. Because of these demonstrated effects, pre-diabetic and diabetic women in particular should be carefully monitored while taking oral contraceptives.

• Asymptomatic gall bladder disease or cholecystectomy.

• Benign liver tumours (focal nodular hyperplasia). There is limited, direct evidence that hormonal contraceptive use does not influence either progression or regression of liver lesions among women with focal nodular hyperplasia.

• Migraine without focal aura. The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent or severe requires discontinuation of oral contraceptives and evaluation of the cause.

• Crohn's disease and ulcerative colitis have been associated with COC use.

If any of the following conditions developed or worsened during a prior pregnancy or during previous COC use, they may occur while taking Lizinna:

• elevated blood pressure

• cholestasis

• herpes gestationis

• otosclerosis

• SLE

• severe headaches

• haemolytic uraemic syndrome

• Sydenham's chorea

• exogenous estrogens may induce or exacerbate symptoms of hereditary and acquired angioedema.

Chloasma

Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking this preparation. Chloasma is often not fully reversible.

Additional contraceptive precautions

When additional contraceptive precautions are required, the patient should be advised either not to have sex, or to use a cap plus spermicide or for her partner to use a condom. Rhythm methods should not be advised as the Pill disrupts the usual cyclical changes associated with the natural menstrual cycle, e.g. changes in temperature and cervical mucus.

Excipients

The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

Potential Reduction in Contraceptive Effectiveness Associated With Co-Administration of Other Drugs:

Hepatic enzyme inducers

Drugs or herbal products that induce enzymes, especially CYP3A4, may decrease the plasma concentrations of contraceptive hormones, and may decrease their effectiveness and/or increase breakthrough bleeding. Enzyme induction may be observed after a few days of treatment. Maximal enzyme induction is generally seen within a few weeks, but may then be sustained for at least 4 weeks after the cessation of medicinal product therapy.

Examples include:

- barbiturates

- bosentan

- carbamazepine

- eslicarbazepine acetate

- felbamate

- (fos)aprepitant

- hydantoins

- primidone

- griseofulvin

- some (combinations of) HIV protease inhibitors (e.g. nelfinavir, ritonavir, ritonavir-boosted protease inhibitors)

- some HCV protease inhibitors (e.g. boceprevir, telaprevir)

- modafinil

- some non-nucleoside reverse transcriptase inhibitors (e.g. nevirapine)

- oxcarbazepine

- phenytoin

- rifampicin and rifabutin

- rufinamide

- St. John's Wort

- topiramate

Drugs that affect absorption

Drugs that increase gastrointestinal motility, e.g. metoclopramide, may reduce hormone absorption.

Treatment with activated charcoal will compromise absorption of steroid hormones.

Colesevelam, a bile acid sequestrant, given together with a combined oral hormonal contraceptive, has been shown to significantly decrease the AUC of ethinylestradiol. No interaction was seen when the contraceptive was given 4 hours before colesevelam.

Management

Long-term

For women on long-term treatment with drugs and herbal products that interact with hormonal contraception, another reliable, non-hormonal method of contraception is recommended.

Short-term

Women on short-term treatment with drugs and herbal products that interact with hormonal contraception and may decrease plasma levels of contraceptive hormones could have their contraceptive effectiveness reduced. They should be advised to use a barrier contraceptive method (e.g. condoms, diaphragm) in addition to Lizinna as follows:

• Women using liver enzyme-inducing drugs should temporarily use a barrier contraceptive method in addition to Lizinna during the time of concomitant medicinal product administration and for 28 days after their discontinuation.

• In the case of modafinil, use of a barrier contraceptive method should continue for 56 days after discontinuation.

If discontinuation of the concomitant medicinal product occurs in week three or runs beyond the end of the tablets in the strip, the next strip should be started without a break.

Increase in Plasma Hormone Levels Associated With Co-administered Drugs:

• etoricoxib

• some HIV protease inhibitors (e.g. atazanavir, indinavir)

Changes in Plasma Levels of Co-Administered Drugs that may be of Clinical Significance:

Combination hormonal contraceptives may also affect the pharmacokinetics of some other drugs if used concomitantly.

Drugs whose plasma levels may be increased (due to CYP inhibition)

Examples include:

• ciclosporin

• prednisolone

• selegiline

• theophylline

• tizanidine

Drugs whose plasma levels may be decreased (due to induction of glucuronidation)

Examples include:

• lamotrigine

Management

Physicians are advised to consult the labelling of concurrently-used drugs to obtain further information about interactions with hormonal contraceptives and the possible need to adjust dosages.

Pharmacodynamic interactions

During clinical trials with patients treated for hepatitis C virus infections (HCV) with medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred significantly more frequently in women using ethinylestradiol-containing medications such as combined hormonal contraceptives (CHCs). Additionally, also in patients treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, ALT elevations were observed in women using ethinylestradiol-containing medications such as CHCs (see section 4.3).

Therefore, Lizinna users must switch to an alternative method of contraception (e.g., progestagen-only contraception or non-hormonal methods) prior to starting therapy with these combination drug regimens. Lizinna can be restarted 2 weeks following completion of treatment with these combination drug regimens.

4.6. Fertility, pregnancy and lactation

Use during pregnancy

Not indicated during pregnancy. Confirm suspected pregnancy before discontinuing treatment.

The majority of recent studies do not indicate a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, when taken inadvertently during early pregnancy.

The increased risk of VTE during the postpartum period should be considered when re-starting Lizinna (see sections 4.2 and 4.4).

Use during lactation

Contraceptive steroids and/or their metabolites may be excreted in breast milk. In addition, combination hormonal contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use Lizinna or other combination hormonal contraceptives but to use other forms of contraception particularly in the first 6 weeks post-partum.

4.7. Effects on ability to drive and use machines

Not applicable.

4.8. Undesirable effects

Description of selected adverse reactions

An increased risk of arterial and venous thrombotic and thromboembolic events, including myocardial infarction, stroke, transient ischemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs. These are discussed in more detail in section 4.4.

These adverse drug reactions (ADRs) require immediate medical attention and/or cessation of oral contraceptive use.

The following ADRs may also require immediate medical attention and/or cessation of CHC use: retinal vein thrombosis, new onset of migraine -type headache, breast cancer, hepatic tumours, adenomas, high blood pressure, angioedema, urticaria and hypersensitivity.

Alternative non-hormonal methods of contraception should be used, while appropriate diagnostic and therapeutic measures are undertaken.

Based on pooled safety data from 5 clinical trials, the most commonly reported (≥10%) ADR was headache (27.9%). The most commonly reported (≥10%) ADR identified during post-marketing experience was diarrhoea (11.8%).

The most common ADRs (≥10%) reported in the first treatment cycle in clinical trials were: dysmenorrhoea (40.4%); nausea (29.1%); metrorrhagia (26.3%); gastrointestinal disorder [reported as nausea or vomiting] (24.6%) and abnormal withdrawal bleeding (16.9%). The incidence of these ADRs was highest in cycle 1 and decreased over time with the exception dysmenorrhoea. The highest incidence of vomiting occurred in cycle 12 (11.8%).

The 5 clinical trials (2 randomised active-controlled trials and 3 uncontrolled open-label trials), which were used to evaluate the safety of , included 1,891 healthy women of child bearing potential. In 3 trials, subjects were followed for up to 24 cycles and in the other 2 trials for up to 12 cycles. An additional uncontrolled study (n=8,331) reported ADRs by treatment cycle for up to 24 cycles. As the frequency of ADRs vary according to the cycle of treatment, the highest cycle incidence has been used to assign the ADR to a frequency category.

The table below displays all ADRs that have been reported with the use of Norgestimate / Ethinylestradiol in clinical trials or from post marketing experiences with norgestimate and ethinyl estradiol tablets.

The displayed frequency categories use the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data).

Infections and infestations

Common

Urinary tract infection, vaginal infection

Neoplasms benign, malignant and unspecified (including cysts and polyps)

Uncommon

Cervical dysplasia

Rare

Breast cyst

Frequency not known

Hepatic adenomas , breast cancer, benign breast neoplasm, focal nodular hyperplasia, fibroadenoma of breast

Immune system disorders

Common

Hypersensitivity

Metabolism and nutrition disorders

Common

Fluid retention

Uncommon

Increase and decrease in appetite, weight fluctuation

Rare

Appetite disorder

Frequency not known

Dyslipidaemia

Psychiatric disorders

Common

Mood altered, depression, nervousness, insomnia

Uncommon

Anxiety, libido disorder

Nervous system disorders

Very common

Headache

Common

Migraine, dizziness

Uncommon

Syncope, paraesthesia

Frequency not known

Cerebrovascular accident, convulsion

Eye disorders

Uncommon

Visual impairment, dry eye

Frequency not known

Intolerance to contact lenses, retinal vascular thrombosis*

Ear and labyrinth disorders

Rare

Vertigo

Cardiac disorders

Uncommon

Palpitations

Rare

Tachycardia

Frequency not known

Myocardial infarction

Vascular disorders

Uncommon

Thrombosis, hypertension, hot flush

Rare

Venous thromboembolism, Arterial thromboembolism

Frequency not known

Deep venous thrombosis*

Respiratory, thoracic and mediastinal disorders

Uncommon

Dyspnoea

Frequency not known

Pulmonary embolism*

Gastrointestinal disorders

Very common

Gastrointestinal disorder, vomiting, diarrhoea, nausea

Common

Gastrointestinal pain, abdominal pain, abdominal distension, constipation, flatulence

Rare

Pancreatitis

Hepato-biliary disorders

Rare

Hepatitis

Frequency not known

Transaminase increased

Skin and subcutaneous tissue disorders

Common

Acne, rash

Uncommon

Alopecia, hirsutism, urticaria, pruritus, erythema, skin discolouration

Rare

Hyperhidrosis, photosensitivity reaction

Frequency not known

Angioedema, erythema nodosum, night sweats

Musculoskeletal and connective tissue disorders

Common

Muscle spasms, pain in extremity, back pain

Uncommon

Myalgia

Reproductive system and breast disorders

Very common

Dysmenorrhoea, metrorrhagia, abnormal withdrawal bleeding

Common

Amenorrhoea, genital discharge, breast pain

Uncommon

Breast discharge, breast enlargement, ovarian cyst, vulvovaginal dryness

Rare

Vaginal discharge

Frequency not known

Suppressed lactation

General disorders and administration site conditions

Common

Chest pain, oedema, asthenic conditions

Investigations

Common

Weight increased

Uncommon

Weight decreased

* Not seen in clinical trials therefore frequency cannot be estimated. See section 4.4 for frequency based on standard reporting rates for similar combined hormonal contraceptives.

Exogenous estrogens may induce or exacerbate symptoms of hereditary and acquired angioedema. (Frequency 'unknown')

4.9. Overdose

There have been no reports of serious ill-health from overdose. Symptoms that may occur are nausea, vomiting and vaginal bleeding. There are no antidotes and further treatment should be symptomatic.

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • ElinNorgestimatum + Ethinylestradiolum · taken by mouth
  • LiberelleNorgestimatum + Ethinylestradiolum · taken by mouth

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Lizinna 250 microgram /35 microgram Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →